Page 75 - Read Online

Nguyen et al. J Transl Genet Genom 2018;2:19 Journal of Translational
DOI: 10.20517/jtgg.2018.20 Genetics and Genomics

Original Article Open Access

Individual xenografts for personalized treatment of
women with metastatic triple negative breast cancer

Thuy T. Nguyen 1,2,3 , Morad El Bouchtaoui , Jean-Paul Feugeas , Laetitia Vercillino , Cédric de Bazelaire 1,6,7 ,
1
4
5
Anne Janin 1,6,8 , Guilhem Bousquet 1,2,8,9
1 INSERM, U1165 Research Unit, Paris F-75010, France.
2 Service d’Oncologie Médicale, AP-HP-Hôpital Avicenne, Bobigny F-93000, France.
3 Department A, National Cancer Hospital, Ha Noi 100000, Viet Nam.
4 INSERM, U1137 Research Unit, Paris F-75890, France.
5 Service de Médecine Nucléaire, AP-HP-Hôpital Saint-Louis, Paris F-75010, France.
6 Laboratoire de Pathologie, Université Paris Diderot, Sorbonne Paris Cité, Paris F-75010, France.
7 Service de Radiologie, AP-HP-Hôpital Saint-Louis, Paris F-75010, France.
8 Laboratoire de Pathologie, AP-HP-Hôpital Saint-Louis, Paris F-75010, France.
9 Université Paris 13, Villetaneuse F-93430, France.

Correspondence to: Dr. Guilhem Bousquet, Service d’Oncologie Médicale, AP-HP-Hôpital Avicenne, Bobigny F-93000, France.
E-mail: guilhem.bousquet@aphp.fr; Dr. Anne Janin, Laboratoire de Pathologie, AP-HP-Hôpital Saint-Louis, Paris F-75010, France.
E-mail: anne.janin1165@gmail.com

How to cite this article: Nguyen TT, El Bouchtaoui M, Feugeas JP, Vercillino L, de Bazelaire C, Janin A, Bousquet G. Individual
xenografts for personalized treatment of women with metastatic triple negative breast cancer. J Transl Genet Genom 2018;2:19.
http://dx.doi.org/10.20517/jtgg.2018.20
Received: 29 Jun 2018 First Decision: 24 Oct 2018 Revised: 31 Oct 2018 Accepted: 1 Nov 2018 Published: 20 Nov 2018

Science Editor: Sheng-Ying Qin Copy Editor: Cui Yu Production Editor: Cai-Hong Wang

Abstract
Aim: Triple negative breast cancer (TNBC) is the most severe subtype of breast cancer with poor prognosis even when
treated at a localized stage. The treatment of metastatic TNBC is still challenging daily clinical practice, mainly because
of the lack of targeted therapies. In the last years, a molecular sub-classification of TNBC has opened the way to
personalized medicine for this type of severe cancer.

Methods: In this study, we assessed the added value of combining molecular analyses with individual xenografts to
personalize the treatment of resort for five women with metastatic TNBC. While a patient was receiving one or two
lines of chemotherapy, the corresponding xenograft model was tested with different drugs or drug combinations, mainly
based on transcriptomic analyses of the tumor and on theoretical activated canonical pathways.

Results: On the basis of transcriptomic analyses and chemosensitivity data obtained from TNBC individual xenografts, we
personalized the resort treatment for the five women in our study. In all cases, despite the fact that this resort treatment

© The Author(s) 2018. Open Access This article is licensed under a Creative Commons Attribution 4.0
International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long
as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license,
and indicate if changes were made.

www.jtggjournal.com